The efficacy of Cavain in patients suffering from anxiety.
The therapeutical efficacy of Cavain should be proved in the treatment of patients suffering from abnormal anxiety, psychosomatic complaints and psychoreactive disorder. Thus two randomized groups of patients (26 each) were treated in double-blind technique with either 2 x 200 mg daily Cavain or placebo for a period of 28 days. Prior to the beginning of the investigations and within 14 days intervals the Hamilton Anxiety Scale (HAMA) and the Adjective Check List (Janke and Debus) were applied. The global therapeutical improvement and compatibility were documented after 14 and 28 days. A significant superiority of Cavain in comparison to placebo could be found. Cavain acted anxiolytically and promotive on the subjective vitality-related performance. Therapeutical conclusions are discussed.
Lehmann
E
E
Psychiatric Clinic, University of Düsseldorf, FRG.
Klieser
E
E
Klimke
A
A
Krach
H
H
Spatz
R
R
D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011714:Pyrans / Q000627:therapeutic use*; D011753:Pyrones / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D014151:Anti-Anxiety Agents; D011714:Pyrans; D011753:Pyrones; C011889:kavain